CORC  > 复旦大学上海医学院
Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
Zhang, Qingyuan; Shao, Zhimin; Shen, Kunwei; Li, Li; Feng, Jifeng; Tong, Zhongsheng; Gu, Kangsheng; Wang, Xiaojia; Xu, Binghe; Sun, Guofang
刊名ONCOTARGET
2016
卷号7期号:35
关键词advanced breast cancer fulvestrant endocrine therapy hormone receptor-positive breast cancer
ISSN号1949-2553
URL标识查看原文
语种英语
内容类型期刊论文
URI标识http://www.corc.org.cn/handle/1471x/3627804
专题复旦大学上海医学院
推荐引用方式
GB/T 7714
Zhang, Qingyuan,Shao, Zhimin,Shen, Kunwei,et al. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China[J]. ONCOTARGET,2016,7(35).
APA Zhang, Qingyuan.,Shao, Zhimin.,Shen, Kunwei.,Li, Li.,Feng, Jifeng.,...&Jiang, Zefei.(2016).Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.ONCOTARGET,7(35).
MLA Zhang, Qingyuan,et al."Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China".ONCOTARGET 7.35(2016).
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace